ONC — BeOne Medicines AG

Summary of BeOne Medicines Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Product Revenue: $1.5 billion, a 32% year-over-year increase.
• BRUKINSA Global Revenue: $1.1 billion in Q4, up 38%, with full-year revenue of $3.9 billion, representing a 49% growth.
• GAAP Profitability: Net income reached $287 million, with GAAP diluted earnings per ADS of $2.53.
• Non-GAAP Metrics: Non-GAAP net income was $918 million, translating to diluted earnings of $8.09 per ADS.
• Free Cash Flow: $380 million in Q4, totaling over $940 million for the year.
• Gross Margin: Improved to 87% from 84% year-over-year.

2. Strategic Updates and Business Highlights

• BRUKINSA: Established as the leading BTK inhibitor globally, showing superior efficacy and safety compared to competitors. Long-term data presented at ASH 2025 reinforced its best-in-class status.
• Pipeline Progress: Significant advancements in R&D, including global approvals for sonro in CLL and MCL, and ongoing Phase III studies for multiple assets.
• Market Positioning: BeOne aims to deepen its leadership in CLL while expanding into other hematological malignancies and solid tumors. The company plans to introduce new therapies that address unmet needs in these areas.
• Innovation Goals: The company aspires to achieve life expectancy for CLL patients equal to the general population and to develop effective fixed-duration therapies.

3. Forward Guidance and Outlook

• 2026 Revenue Projection: Expected to be between $6.2 billion and $6.4 billion, driven by continued demand for BRUKINSA and new product launches.
• Operating Expenses: Anticipated to be between $4.7 billion and $4.9 billion, reflecting ongoing investments in commercial growth and R&D.
• GAAP Operating Income: Projected between $700 million and $800 million, with non-GAAP operating income expected between $1.4 billion and $1.5 billion.

4. Bad News, Challenges, or Points of Concern

• Competitive Landscape: Concerns about potential pricing pressures as competitors enter the market and the impact of CMS drug price negotiations on overall pricing dynamics.
• Fixed Duration Therapies: Current fixed-duration options have shown inferior efficacy and safety profiles compared to continuous BTK inhibitors, which may limit their uptake.
• Regulatory Risks: The timeline for the BTK degrader's accelerated approval remains uncertain, with potential delays impacting market entry.

5. Notable Q&A Insights

• Pricing Strategy: Management emphasized the differentiated value proposition of BRUKINSA, which they believe will sustain its market position despite competitive pressures.
• Market Dynamics: The company is confident in capturing market share from competitors like Calquence and IMBRUVICA due to BRUKINSA's superior clinical data.
• Immunology Pipeline: BeOne is exploring opportunities in immunology, with plans to identify cornerstone therapies over the next few years.
• Fixed Duration vs. Continuous Therapy: Management acknowledged the complexities of introducing fixed-duration therapies without cannibalizing BRUKINSA's market share, emphasizing the need for strong clinical data to support new offerings.

Overall, BeOne Medicines reported a strong financial performance in 2025, with significant growth in its leading product, BRUKINSA, and a promising pipeline. However, the company faces challenges from competitive pressures and the need to navigate the evolving treatment landscape in hematology and oncology.